Am J Health-Syst Pharm
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ferron, G.
Right arrow Articles by Paul, J
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ferron, G.
Right arrow Articles by Paul, J
American Journal of Health-System Pharmacy, Vol 60, Issue 13, 1324-1329
Copyright © 2003 by American Society of Health-System Pharmacists

Articles

Oral bioavailability of pantoprazole suspended in sodium bicarbonate solution

GM Ferron, S Ku, M Abell, M Unruh, J Getsy, PR Mayer, and J Paul


The bioavailability of pantoprazole when administered as a suspension in sodium bicarbonate solution and as the oral tablet was studied. In an open-label, randomized, two-period crossover study, healthy fasting subjects received either one enteric-coated 40-mg pantoprazole tablet by mouth with 240 mL of water or 20 mL of a suspension prepared from one crushed pantoprazole tablet and 840 mg of sodium bicarbonate solution and administered via a nasogastric tube. Treatments were separated by a 48-hour washout period. Blood samples were collected at intervals up to 24 hours after drug administration for measurement of pantoprazole concentration by high-performance liquid chromatography (HPLC) and estimation of pharmacokinetic values. A separate study was conducted to determine pantoprazole's stability in the suspension for up to three months at 25, 5, and -20 degrees C; concentrations were measured by HPLC. Twelve subjects completed the study. The suspension yielded pantoprazole Cmax values similar to those of the tablet formulation, but the drug was 25% less bioavailable. There was no lag time for the suspension. The suspension was stable for up to two weeks at 5 degrees C and up to three months at -20 degrees C. A suspension of pantoprazole in sodium bicarbonate solution yielded a Cmax similar to that of the tablet formulation, and the drug was quickly absorbed. However, bio-availability was slightly lower with the suspension than with the tablet.
 



This article has been cited by other articles:


Home page
 Am J Health Syst PharmHome page
N. T. Williams
Medication administration through enteral feeding tubes
Am. J. Health Syst. Pharm., December 15, 2008; 65(24): 2347 - 2357.
[Abstract] [Full Text] [PDF]

Home page
 Am J Health Syst PharmHome page
J. E. Burnett and E. R. Balkin
Stability and viscosity of a flavored omeprazole oral suspension for pediatric use
Am. J. Health Syst. Pharm., November 15, 2006; 63(22): 2240 - 2247.
[Abstract] [Full Text] [PDF]

Home page
 Am J Health Syst PharmHome page
C. E. JOHNSON
Stability of pantoprazole in 0.9% sodium chloride injection in polypropylene syringes
Am. J. Health Syst. Pharm., November 15, 2005; 62(22): 2410 - 2412.
[Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
J. W Devlin, L. S Welage, and K. M Olsen
Proton Pump Inhibitor Formulary Considerations in the Acutely Ill Part 1: Pharmacology, Pharmacodynamics, and Available Formulations
Ann. Pharmacother., October 1, 2005; 39(10): 1667 - 1677.
[Abstract] [Full Text] [PDF]

Home page
 Am J Health Syst PharmHome page
L. S. Welage
Overview of pharmacologic agents for acid suppression in critically ill patients
Am. J. Health Syst. Pharm., May 15, 2005; 62(10_Supplement_2): S4 - S10.
[Abstract] [Full Text] [PDF]

Home page
 Am J Health Syst PharmHome page
J. W. Devlin
Proton pump inhibitors for acid suppression in the intensive care unit: Formulary considerations
Am. J. Health Syst. Pharm., May 15, 2005; 62(10_Supplement_2): S24 - S30.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 by the American Society of Health-System Pharmacists.